bioRxivCancer Biology
Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcoma
S. G. Danielli, Y. Wei, M. A. Dyer, E. Stewart, M. Wachtel, B. W. Schaefer, A. G. Patel, D. M. Langenau
Abstract
Rhabdomyosarcoma (RMS) is a pediatric tumor that resembles undifferentiated muscle cells; yet the extent to which cell state heterogeneity and molecular features are shared with human development have not been fully ascribed. Here, we report a single-cell/nucleus RNA sequencing atlas derived from 72 datasets that includes patient tumors, patient-derived xenografts, primary in vitro cultures, and established cell lines. We report four dominant muscle-lineage cell states in RMS: progenitors, proliferative, differentiated, and ground cells. We stratify these RMS cells along the continuum of human muscle development and show that RMS cells share expression patterns with fetal/embryonal myogenic precursors rather than postnatal satellite cells. Indeed, fusion-negative RMS (FN-RMS) have a discrete stem cell hierarchy that faithfully recapitulates fetal muscle development. We also identify therapy-resistant FN-RMS progenitor cells that share transcriptomic similarity with bipotent skeletal mesenchymal cells, while a subset of fusion-positive (FP) RMS have tumor-acquired cells states, including a neuronal cell state, that are not found in development. Chemotherapy induced upregulation of progenitor signatures in FN-RMS while the neuronal gene programs were retained after therapy in FP-RMS. Taken together, this work identifies new cell state heterogeneity including unique treatment-resistant and tumor-acquired cell states that differ across RMS subtypes.
- organism: human
- assay: scRNA-seq
- research focus: cell type annotation
- research focus: clustering
- research focus: differential expression
- research focus: cell-cell communication
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Single-cell mapping of tumor heterogeneity in pediatric rhabdomyosarcoma reveals developmental signatures with therapeutic relevance
S. G. Danielli, E. Porpiglia, … B. W. Schäfer·bioRxiv·Apr 20, 2022
- Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma.
J. DeMartino, M. T. Meister, … J. Drost·bioRxiv·Jul 15, 2022
- SIX1 Reprograms Myogenic Transcription Factors to Maintain the Rhabdomyosarcoma undifferentiated state
J. Y. Hsu, E. P. Danis, … H. L. Ford·bioRxiv·Apr 25, 2021
- The Myogenesis Program Drives Clonal Selection and Drug Resistance in Rhabdomyosarcoma
A. G. Patel, X. Chen, … M. A. Dyer·bioRxiv·Jun 16, 2021
- Fusion-negative Rhabdomyosarcoma 3D-organoids as an innovative model to predict resistance to cell death inducers
C. Savary, P. Huchede, … L. Broutier·bioRxiv·Sep 6, 2022
- PROX1 transcription factor is a master regulator of myogenic and oncogenic features of rhabdomyosarcoma
N. Y. Gizaw, P. Kallio, … R. Kivela·bioRxiv·Apr 19, 2020